Nika Pharmaceuticals, Inc financial data

Symbol
NIKA on OTC
Industry
Pharmaceutical Preparations
Location
2269 Merrimack Valley Avenue, Henderson, NV
State of incorporation
CO
Fiscal year end
December 31
Former names
CENTENNIAL GROWTH EQUITIES INC (to 8/15/2022)
Latest financial report
10-Q - Q2 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 23.4 % +89.7%
Debt-to-equity -170 % -48.8%
Return On Equity 75.3 % -55.4%
Return On Assets -94.7 % +90.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.02B shares +16.3%
Common Stock, Shares, Outstanding 1.02B shares +16.3%
Entity Public Float 0 USD
Common Stock, Value, Issued 102K USD +16.3%
Weighted Average Number of Shares Outstanding, Basic 1.02B shares +16.3%
Weighted Average Number of Shares Outstanding, Diluted 1.02B shares +16.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 156 USD
General and Administrative Expense 107K USD +110%
Operating Income (Loss) -109K USD -71.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -109K USD -71.8%
Net Income (Loss) Attributable to Parent -109K USD -114%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.39K USD -87.3%
Accounts Receivable, after Allowance for Credit Loss, Current 196K USD
Inventory, Net 14.1K USD
Assets, Current 1.39K USD -87.3%
Property, Plant and Equipment, Net 168K USD
Assets 1.39K USD -87.3%
Accounts Payable, Current 1.5K USD
Liabilities, Current 210K USD +145%
Liabilities 210K USD +145%
Retained Earnings (Accumulated Deficit) -8.92M USD -163%
Stockholders' Equity Attributable to Parent -209K USD -179%
Liabilities and Equity 1.39K USD -87.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -150K USD -667%
Net Cash Provided by (Used in) Financing Activities 155K USD +569%
Common Stock, Shares Authorized 2.7B shares 0%
Common Stock, Shares, Issued 1.02B shares +16.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.87K USD +35.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.39K USD -87.3%
Deferred Tax Assets, Valuation Allowance 714K USD +2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -8.37K USD +17.5%
Deferred Tax Assets, Operating Loss Carryforwards 714K USD +2%
Preferred Stock, Shares Issued 15M shares +50%
Preferred Stock, Shares Authorized 15M shares +50%
Additional Paid in Capital 8.6M USD +166%
Preferred Stock, Shares Outstanding 15M shares +50%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%